Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease

Author(s): Miura K, Ohnishi H1

Abstract

Emerging data have shown a close association between compositional changes in gut microbiota and the development of nonalcoholic fatty liver disease (NAFLD). The change in gut microbiota may alter nutritional absorption and storage. In addition, gut microbiota are a source of Toll-like receptor (TLR) ligands, and their compositional change can also increase the amount of TLR ligands delivered to the liver. TLR ligands can stimulate liver cells to produce proinflammatory cytokines. Therefore, the gut-liver axis has attracted much interest, particularly regarding the pathogenesis of NAFLD. The abundance of the major gut microbiota, including Firmicutes and Bacteroidetes, has been considered a potential underlying mechanism of obesity and NAFLD, but the role of these microbiota in NAFLD remains unknown. Several reports have demonstrated that certain gut microbiota are associated with the development of obesity and NAFLD. For instance, a decrease in Akkermansia muciniphila causes a thinner intestinal mucus layer and promotes gut permeability, which allows the leakage of bacterial components. Interventions to increase Akkermansia muciniphila improve the metabolic parameters in obesity and NAFLD. In children, the levels of Escherichia were significantly increased in nonalcoholic steatohepatitis (NASH) compared with those in obese control. Escherichia can produce ethanol, which promotes gut permeability. Thus, normalization of gut microbiota using probiotics or prebiotics is a promising treatment option for NAFLD. In addition, TLR signaling in the liver is activated, and its downstream molecules, such as proinflammatory cytokines, are increased in NAFLD. To data, TLR2, TLR4, TLR5, and TLR9 have been shown to be associated with the pathogenesis of NAFLD. Therefore, gut microbiota and TLRs are targets for NAFLD treatment.

Similar Articles

Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review

Author(s): Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, et al.

Gut microbiota and non-alcoholic fatty liver disease: new insights

Author(s): Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Author(s): Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al.

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Role of gut microbiota: obesity and NAFLD

Author(s): Gangarapu V, Yıldız K, Ince AT, Baysal B

Hepatic histology in obese patients undergoing bariatric surgery

Author(s): Machado M, Marques-Vidal P, Cortez-Pinto H

Gut microbiota and liver disease

Author(s): Goel A, Gupta M, Aggarwal R

An obesity-associated gut microbiome with increased capacity for energy harvest

Author(s): Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al.

Obesity alters gut microbial ecology

Author(s): Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, et al.

Microbial ecology: human gut microbes associated with obesity

Author(s): Ley RE, Turnbaugh PJ, Klein S, Gordon JI

Microbiota and SCFA in lean and overweight healthy subjects

Author(s): Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, et al.

Human colonic microbiota associated with diet, obesity and weight loss

Author(s): Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al.

Enterotypes of the human gut microbiome

Author(s): Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al.

The gut microbiota as an environmental factor that regulates fat storage

Author(s): Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al.

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

Author(s): Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI

Human gut microbiota in obesity and after gastric bypass

Author(s): Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, et al.

The gut microbiota, obesity and insulin resistance

Author(s): Shen J, Obin MS, Zhao L

Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice

Author(s): Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, et al.

The role of gut microbiota on insulin resistance

Author(s): Caricilli AM, Saad MJ

Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance

Author(s): Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al.

NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance

Author(s): Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, et al.

Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis

Author(s): Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, et al.

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

Author(s): Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al.

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

Author(s): Rivera CA, Gaskin L, Allman M, Pang J, Brady K, et al.

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5

Author(s): Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, et al.

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis

Author(s): Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al.

A functional role for Nlrp6 in intestinal inflammation and tumorigenesis

Author(s): Chen GY, Liu M, Wang F, Bertin J, Núñez G

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Author(s): Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al.

NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion

Author(s): Wlodarska M, Thaiss CA2, Nowarski R3, Henao-Mejia J3, Zhang JP4, et al.

NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens

Author(s): Anand PK, Malireddi RK, Lukens JR, Vogel P, Bertin J, et al.

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

Author(s): Bergheim I, Weber S, Vos M, Krämer S, Volynets V, et al.

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

Author(s): Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB

Review article: prebiotics in the gastrointestinal tract

Author(s): Macfarlane S, Macfarlane GT, Cummings JH

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis

Author(s): Ma YY, Li L, Yu CH, Shen Z, Chen LH, et al.